Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2020

Open Access 01-12-2020 | Acute Myeloid Leukemia | Case report

Adult Langerhans cell histiocytosis presenting with multisystem involvement and sarcomatoid features: a case report

Authors: Luis E. Aguirre, Ingrid Schwartz, Jennifer Chapman, Marcelo F. Larsen, Alvaro Alencar

Published in: Journal of Medical Case Reports | Issue 1/2020

Login to get access

Abstract

Background

Langerhans cell tumors are rare clonal disorders characterized by neoplastic proliferation of dendritic cells that can be further classified into the subtypes Langerhans cell histiocytosis and Langerhans cell sarcoma, which are rare neoplasms exhibiting aggressive features and a poor prognosis. In addition to illustrating the refractoriness and poor outcomes of multisystem Langerhans cell histiocytosis in adults, specific events in this case highlight important characteristics of disease biology that warrant detailed discussion and exposition to a wider audience.

Case presentation

We describe the case of a 42-year-old Caucasian man with Langerhans cell histiocytosis diagnosed from a lesion on the left arm that presented with constitutional symptoms, early satiety, and weight loss. Esophagogastroduodenoscopy showed extensive esophageal and duodenal involvement by Langerhans cell histiocytosis with features of Langerhans cell sarcoma. He was initially treated for Langerhans cell histiocytosis with low doses of cytarabine until he eventually presented clear transformation to acute monoblastic leukemia with complex karyotype that could not be properly controlled, leading eventually to death.

Conclusions

Langerhans cell histiocytosis remains an exceedingly rare entity in adults, frequently presenting as multisystem disease with risk organ involvement. Langerhans cell sarcoma represents an aggressive subtype with extremely poor prognosis for which intensive acute myeloid leukemia induction should be strongly considered.
Literature
1.
go back to reference Stockschlaeder M, Sucker C. Adult Langerhans cell histiocytosis. Eur J Haematol. 2006;76:363–8.CrossRef Stockschlaeder M, Sucker C. Adult Langerhans cell histiocytosis. Eur J Haematol. 2006;76:363–8.CrossRef
2.
go back to reference Broadbent V, Egeler RM, Nesbit ME Jr. Langerhans cell histiocytosis: clinical and epidemiological aspects. Br J Cancer Suppl. 1994;23:S11–6.PubMedPubMedCentral Broadbent V, Egeler RM, Nesbit ME Jr. Langerhans cell histiocytosis: clinical and epidemiological aspects. Br J Cancer Suppl. 1994;23:S11–6.PubMedPubMedCentral
3.
go back to reference Baumgartner I, von Hochstetter A, Baumert B, et al. Langerhans’-cell histiocytosis in adults. Med Pediatr Oncol. 1997;28(1):9–14.CrossRef Baumgartner I, von Hochstetter A, Baumert B, et al. Langerhans’-cell histiocytosis in adults. Med Pediatr Oncol. 1997;28(1):9–14.CrossRef
4.
go back to reference Lahey ME. Histiocytosis-X: an analysis of prognostic factors. J Pediatr. 1975;87:184–9.CrossRef Lahey ME. Histiocytosis-X: an analysis of prognostic factors. J Pediatr. 1975;87:184–9.CrossRef
5.
go back to reference Saven A, Figueroa ML, Piro LD, et al. 2-Chlorodeoxyadenosine to treat refractory histiocytosis X. N Engl J Med. 1993;329(10):734–5.CrossRef Saven A, Figueroa ML, Piro LD, et al. 2-Chlorodeoxyadenosine to treat refractory histiocytosis X. N Engl J Med. 1993;329(10):734–5.CrossRef
6.
go back to reference Badalian-Very G, Vergilio JA, Degar B, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116(11):1919–23.CrossRef Badalian-Very G, Vergilio JA, Degar B, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116(11):1919–23.CrossRef
7.
go back to reference Sahm F, Capper D, Preusser M, et al. BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood. 2012;120(12):e28–34.CrossRef Sahm F, Capper D, Preusser M, et al. BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood. 2012;120(12):e28–34.CrossRef
8.
go back to reference Arcico M, Girschikofsky M, Genereau T, et al. Langerhans cell histiocytosis in adults: report from the International Registry of the Histiocytic Society. Eur J Cancer. 2003;39:2341–8.CrossRef Arcico M, Girschikofsky M, Genereau T, et al. Langerhans cell histiocytosis in adults: report from the International Registry of the Histiocytic Society. Eur J Cancer. 2003;39:2341–8.CrossRef
9.
go back to reference French Langerhans’ Cell Histiocytosis Study Group. A multicentre retrospective survey of Langerhans’ cell histiocytosis: 348 cases observed between 1983 and 1993. Arch Dis Child. 1996;75(1):17–24.CrossRef French Langerhans’ Cell Histiocytosis Study Group. A multicentre retrospective survey of Langerhans’ cell histiocytosis: 348 cases observed between 1983 and 1993. Arch Dis Child. 1996;75(1):17–24.CrossRef
10.
go back to reference Singhi AD, Montgomery EA. Gastrointestinal tract Langerhans cell histiocytosis: a clinicopathologic study of 12 patients. Am J Surg Pathol. 2011;35(2):305–10.CrossRef Singhi AD, Montgomery EA. Gastrointestinal tract Langerhans cell histiocytosis: a clinicopathologic study of 12 patients. Am J Surg Pathol. 2011;35(2):305–10.CrossRef
11.
go back to reference Zwerdling T, Won E, Shane L, et al. Langerhans cell sarcoma: case report and review of world literature. J Pediatr Hematol Oncol. 2014;36(6):419–25.CrossRef Zwerdling T, Won E, Shane L, et al. Langerhans cell sarcoma: case report and review of world literature. J Pediatr Hematol Oncol. 2014;36(6):419–25.CrossRef
12.
go back to reference Howard JE, Dwivedi RC, Masterson L, et al. Langerhans cell sarcoma: a systematic review. Cancer Treat Rev. 2015;41(4):320–31.CrossRef Howard JE, Dwivedi RC, Masterson L, et al. Langerhans cell sarcoma: a systematic review. Cancer Treat Rev. 2015;41(4):320–31.CrossRef
13.
go back to reference Nakamine H, Yamakawa M, Yoshino T, et al. Langerhans cell histiocytosis and Langerhans cell sarcoma: current understanding and differential diagnosis. J Clin Exp Hematop. 2016;56(2):109–18.CrossRef Nakamine H, Yamakawa M, Yoshino T, et al. Langerhans cell histiocytosis and Langerhans cell sarcoma: current understanding and differential diagnosis. J Clin Exp Hematop. 2016;56(2):109–18.CrossRef
14.
go back to reference Ferringer T, Banks PM, Metcalf JS. Langerhans cell sarcoma. Am J Dermatopathol. 2006;28:36–9.CrossRef Ferringer T, Banks PM, Metcalf JS. Langerhans cell sarcoma. Am J Dermatopathol. 2006;28:36–9.CrossRef
15.
go back to reference Pileri S, Grogan TM, Harris NL, et al. Tumors of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study group based on 61 cases. Histopathology. 2002;41:1–29.CrossRef Pileri S, Grogan TM, Harris NL, et al. Tumors of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study group based on 61 cases. Histopathology. 2002;41:1–29.CrossRef
16.
go back to reference Duan MH, Han X, Li J, et al. Comparison of vindesine and prednisone and cyclophosphamide, etoposide, vindesine, and prednisone as first-line treatment for adult Langerhans cell histiocytosis: a single-center retrospective study. Leuk Res. 2016;42:43–6.CrossRef Duan MH, Han X, Li J, et al. Comparison of vindesine and prednisone and cyclophosphamide, etoposide, vindesine, and prednisone as first-line treatment for adult Langerhans cell histiocytosis: a single-center retrospective study. Leuk Res. 2016;42:43–6.CrossRef
17.
go back to reference Girschikofsky M, Arico M, Castillo D, et al. Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net. Orphanet J Rare Dis. 2013;8:72.CrossRef Girschikofsky M, Arico M, Castillo D, et al. Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net. Orphanet J Rare Dis. 2013;8:72.CrossRef
18.
go back to reference Cantu MA, Lupo PJ, Bilgi M, et al. Optimal therapy for adults with Langerhans cell histiocytosis bone lesions. PLoS One. 2012;7(8):e43257.CrossRef Cantu MA, Lupo PJ, Bilgi M, et al. Optimal therapy for adults with Langerhans cell histiocytosis bone lesions. PLoS One. 2012;7(8):e43257.CrossRef
19.
go back to reference Haroche J, Cohen-Aubart F, Emile JF, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013;121(9):1495–500.CrossRef Haroche J, Cohen-Aubart F, Emile JF, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013;121(9):1495–500.CrossRef
20.
go back to reference Veys PA, Nanduri V, Baker KS, et al. Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: outcome by intensity of conditioning. Br J Haematol. 2015;169(5):711–8.CrossRef Veys PA, Nanduri V, Baker KS, et al. Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: outcome by intensity of conditioning. Br J Haematol. 2015;169(5):711–8.CrossRef
21.
go back to reference Saven A, Foon KA, Piro LD, et al. 2-Chlorodeoxyadenosine-induced complete remissions in Langerhans-cell histiocytosis. Ann Intern Med. 1994;121(6):430–2.CrossRef Saven A, Foon KA, Piro LD, et al. 2-Chlorodeoxyadenosine-induced complete remissions in Langerhans-cell histiocytosis. Ann Intern Med. 1994;121(6):430–2.CrossRef
22.
go back to reference Morimoto A, Oh Y, Nakamura S, et al. Inflammatory serum cytokines and chemokines increase associated with the disease extent in pediatric Langerhans cell histiocytosis. Cytokine. 2017;97:73–9.CrossRef Morimoto A, Oh Y, Nakamura S, et al. Inflammatory serum cytokines and chemokines increase associated with the disease extent in pediatric Langerhans cell histiocytosis. Cytokine. 2017;97:73–9.CrossRef
23.
go back to reference Kannourakis G, Abbas A. The role of cytokines in the pathogenesis of Langerhans cell histiocytosis. Br J Cancer Suppl. 1994;23:S37–40.PubMedPubMedCentral Kannourakis G, Abbas A. The role of cytokines in the pathogenesis of Langerhans cell histiocytosis. Br J Cancer Suppl. 1994;23:S37–40.PubMedPubMedCentral
24.
go back to reference Xerri L, Adélaïde J, Popovici C, et al. CDKN2A/B deletion and double-hit mutations of the MAPK pathway underlie the aggressive behavior of Langerhans cell tumors. Am J Surg Pathol. 2018;42(2):150–9.CrossRef Xerri L, Adélaïde J, Popovici C, et al. CDKN2A/B deletion and double-hit mutations of the MAPK pathway underlie the aggressive behavior of Langerhans cell tumors. Am J Surg Pathol. 2018;42(2):150–9.CrossRef
Metadata
Title
Adult Langerhans cell histiocytosis presenting with multisystem involvement and sarcomatoid features: a case report
Authors
Luis E. Aguirre
Ingrid Schwartz
Jennifer Chapman
Marcelo F. Larsen
Alvaro Alencar
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2020
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-020-02460-3

Other articles of this Issue 1/2020

Journal of Medical Case Reports 1/2020 Go to the issue